Pharmacist-led Protocol Improves Iron Deficiency Screening And IV Iron Replacement In Heart Failure Patients
Jamila Alaryani,Yosef Manla,Emna Abidi,Mohamed Hisham,Obada Kholoki,Firas Al Badarin,Feras Bader,Bassam Atallah
DOI: https://doi.org/10.1016/j.cardfail.2023.10.107
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Iron deficiency (ID) is a common co-morbidity in patients with HF, irrespective of anemia status, and is associated with reduced functional capacity, and quality of life. The recent European Society of Cardiology HF guidelines recommend screening all HF patients and considering IV Ferric carboxymaltose replacement (IV-FCMR) in patients with ID and symptomatic HF (NYHA class ≥II) with an LVEF <45%. However, the implementation of screening and treating ID in this cohort of patients is still lacking in clinical practice. Therefore, we sought to examine the efficacy and feasibility of a pharmacist-led protocol (PLP) to improve the screening for ID and IV-FCMR in HF patients with LVEF<45%. Methods Our study included two cohorts; the pre-PLP (Oct 2015-Feb 2020, n=432) and the post-PLP (Aug 2022- Jan 2023, n=154), who followed up at our HF clinic in the Middle East Gulf region. We included patients with symptomatic HF (NYHA class ≥II) and LVEF <45%. A PLP for screening for ID (defined as having low ferritin (<100 μg/L) or intermediate ferritin (≥100 μg/L but <300 μg/L, with a low Transferrin saturation (TSAT) of <20%) and IV-FCMR was introduced to our hospital policies and implemented in Aug-2022. When ID criteria are met in screened patients, IV-FCMR is ordered by the pharmacist with the approval of the treating HF physician. Data on patient characteristics and laboratory findings were collected retrospectively and compared between cohorts using appropriate testing methods. Results After PLP implementation, there was an increase of 37% in the likelihood of ID screening (Post-PLP:86.4% (133) vs. Pre-PLP:63.2% (273), OR:1.37, 95%CI [1.04-1.8], P=0.03). When comparing patients screened for ID in both cohorts, there were no statistically significant differences in patient demographics and comorbidities (Table). However, screened patients in the post-PLP group had higher levels of hemoglobin (P=0.01), serum ferritin (P=0.002), serum iron, iron (<0.001), and TSAT% (<0.001). Screened patients in the post-PLP cohort were less likely to be diagnosed with ID (53.4% (71) vs. 80.6% (220), OR:0.27, 95%CI [0.17-0.43], P<0.001). Among patients with ID, the PLP was associated with increased rates of IV-FCMR (Post-PLP: 73 (52) vs. Pre-PLP: 30.4% (67), OR:6.2, 95%CI [3.4-11.4], P<0.001). Conclusion In patients with symptomatic HF and LVEF<45%, a PLP successfully increases screening for ID as well as IV iron replacement therapy when indicated. While there is still a need to further investigate the impact of IV-FCMR on clinical outcomes beyond functional capacity and quality of life, multidisciplinary collaborative protocols and pharmacist-led initiatives can be replicated in many settings to improve implementation of evidence-based therapies and guidelines.
cardiac & cardiovascular systems